{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:10:00Z","timestamp":1789603800347,"version":"build-2803163510"},"reference-count":45,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Thyroid dysfunction is frequently caused by treatment with antiprogrammed cell death-1 ligand 1 antibodies (PD-L1-Abs) and anticancer drugs, including ramucirumab (RAM) and multitargeted tyrosine kinase inhibitors (multi-TKIs), which are often used prior to PD-L1-Ab treatment in cancer patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 148 patients treated with PD-L1-Abs were evaluated for antithyroid antibodies at baseline and for thyroid function every 6 weeks for 24 weeks after treatment initiation and then were observed until the visits stopped.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 148 patients, 15 (10.1%) developed thyroid dysfunction after PD-L1-Ab treatment (destructive thyroiditis in 8 and hypothyroidism without preceding thyrotoxicosis in 7). The prevalence of an elevated thyroid-stimulating hormone (TSH) level at baseline (3\/15 [20.0%] vs 4\/133 [3.0%], P\u2005&amp;lt;\u2005.05), positive antithyroglobulin antibodies (TgAbs) at baseline (4\/15 [26.7%] vs 5\/133 [3.8%], P\u2005&amp;lt;\u2005.05) and prior treatment with RAM or multi-TKIs (3\/15 [20.0%] vs 5\/133 [3.8%], P\u2005&amp;lt;\u2005.05) were significantly higher in patients with vs without thyroid dysfunction. In a multivariate analysis, elevated TSH level at baseline, TgAb positivity at baseline, and prior treatment with RAM or multi-TKIs were significantly associated with the development of thyroid dysfunction, with ORs of 7.098 (95% CI 1.154-43.638), 11.927 (95% CI 2.526-56.316), and 8.476 (95% CI 1.592\u201345.115), respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The results of this real-world study suggest that the risk of thyroid dysfunction induced by PD-L1-Abs can be predicted by the TSH level at baseline, TgAb positivity at baseline, and prior treatment with RAM or multi-TKIs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgac467","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T02:54:00Z","timestamp":1659495240000},"page":"e4115-e4123","source":"Crossref","is-referenced-by-count":23,"title":["Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade"],"prefix":"10.1210","volume":"107","author":[{"given":"Tomoko","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3281-0337","authenticated-orcid":false,"given":"Shintaro","family":"Iwama","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayana","family":"Yamagami","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Okuji","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Ando","sequence":"additional","affiliation":[{"name":"Center for Advanced Medicine and Clinical Research, Nagoya University Hospital , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Onoue","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Miyata","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Hagiwara","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1924-7639","authenticated-orcid":false,"given":"Hidetaka","family":"Suga","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Banno","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine , Nagoya , Japan"},{"name":"Research Center of Health, Physical Fitness and Sports, Nagoya University , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9653-8424","authenticated-orcid":false,"given":"Tetsunari","family":"Hase","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Morise","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3203-3766","authenticated-orcid":false,"given":"Toyone","family":"Kikumori","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naozumi","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3746-1997","authenticated-orcid":false,"given":"Hiroshi","family":"Arima","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"issue":"17","key":"2022092808412400200_CIT0001","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"2022092808412400200_CIT0002","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1507\/endocrj.EJ19-0163","article-title":"Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society","volume":"66","author":"Arima","year":"2019","journal-title":"Endocr J"},{"issue":"1","key":"2022092808412400200_CIT0003","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J ImmunoTher Cancer."},{"issue":"2","key":"2022092808412400200_CIT0004","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3803\/EnM.2021.1007","article-title":"Clinical characteristics, management, and potential biomarkers of endocrine dysfunction induced by immune checkpoint inhibitors","volume":"36","author":"Iwama","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"3","key":"2022092808412400200_CIT0005","first-page":"101660","article-title":"Immune checkpoint inhibitor-related thyroid dysfunction","volume":"36","author":"Iwama","year":"2022","journal-title":"Best"},{"issue":"7","key":"2022092808412400200_CIT0006","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonzalez-Rodriguez","year":"2016","journal-title":"Oncologist"},{"issue":"3","key":"2022092808412400200_CIT0007","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2217\/imt-2016-0147","article-title":"Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis","volume":"9","author":"Shang","year":"2017","journal-title":"Immunotherapy"},{"issue":"2","key":"2022092808412400200_CIT0008","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol."},{"issue":"9","key":"2022092808412400200_CIT0009","doi-asserted-by":"crossref","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following immune checkpoint inhibitor treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022092808412400200_CIT0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev."},{"issue":"4","key":"2022092808412400200_CIT0011","doi-asserted-by":"crossref","first-page":"e1620","DOI":"10.1210\/clinem\/dgab829","article-title":"Increased risk of thyroid dysfunction by PD-1 and CTLA-4 blockade in patients without thyroid autoantibodies at baseline","volume":"107","author":"Iwama","year":"2022","journal-title":"J Clin Endocrinol Metab."},{"issue":"20","key":"2022092808412400200_CIT0012","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med."},{"issue":"2","key":"2022092808412400200_CIT0013","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"issue":"11","key":"2022092808412400200_CIT0014","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1111\/cas.13800","article-title":"Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab","volume":"109","author":"Kimbara","year":"2018","journal-title":"Cancer Sci."},{"issue":"3","key":"2022092808412400200_CIT0015","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J Endocr Soc."},{"issue":"6","key":"2022092808412400200_CIT0016","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41416-020-0736-7","article-title":"Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study","volume":"122","author":"Okada","year":"2020","journal-title":"Br J Cancer."},{"issue":"9944","key":"2022092808412400200_CIT0017","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet."},{"issue":"2","key":"2022092808412400200_CIT0018","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/1759-7714.14236","article-title":"Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: a retrospective study","volume":"13","author":"Ishida","year":"2022","journal-title":"Thorac Cancer"},{"issue":"4","key":"2022092808412400200_CIT0019","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1248\/bpb.b19-01071","article-title":"Thyroid dysfunction related to the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab: a series of 14 cases and a descriptive study","volume":"43","author":"Dote","year":"2020","journal-title":"Biol Pharm Bull."},{"key":"2022092808412400200_CIT0020","year":"2015."},{"issue":"3","key":"2022092808412400200_CIT0021","doi-asserted-by":"crossref","first-page":"R91","DOI":"10.1530\/EJE-14-0198","article-title":"Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors","volume":"171","author":"Illouz","year":"2014","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"2022092808412400200_CIT0022","doi-asserted-by":"crossref","first-page":"32","DOI":"10.17925\/EE.2020.16.1.32","article-title":"Anticancer drug-induced thyroid dysfunction","volume":"16","author":"Bhattacharya","year":"2020","journal-title":"Eur Endocrinol"},{"issue":"19","key":"2022092808412400200_CIT0023","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res."},{"issue":"5","key":"2022092808412400200_CIT0024","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jnci\/djj069","article-title":"BAY 43-9006 inhibition of oncogenic RET mutants","volume":"98","author":"Carlomagno","year":"2006","journal-title":"J Natl Cancer Inst."},{"key":"2022092808412400200_CIT0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-3-642-01222-8_5","article-title":"Sorafenib","volume":"184","author":"Hasskarl","year":"2010","journal-title":"Recent Results Cancer Res."},{"key":"2022092808412400200_CIT0026","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2045-824X-6-18","article-title":"Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage","volume":"6","author":"Yamamoto","year":"2014","journal-title":"Vasc Cell"},{"issue":"3","key":"2022092808412400200_CIT0027","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cen.14135","article-title":"Thyroid disorders in programmed death-1 inhibitors treated patients: is previous therapy with tyrosine kinase inhibitors a predisposing factor?","volume":"92","author":"Sbardella","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2022092808412400200_CIT0028","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J ImmunoTher Cancer."},{"issue":"3","key":"2022092808412400200_CIT0029","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol."},{"issue":"11","key":"2022092808412400200_CIT0030","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"de Filette","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2022092808412400200_CIT0031","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2022092808412400200_CIT0032","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1507\/endocrj.EJ20-0436","article-title":"Anti-pituitary antibodies as a marker of autoimmunity in pituitary glands","volume":"67","author":"Iwama","year":"2020","journal-title":"Endocr J."},{"issue":"5","key":"2022092808412400200_CIT0033","doi-asserted-by":"crossref","first-page":"e002493","DOI":"10.1136\/jitc-2021-002493","article-title":"Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors","volume":"9","author":"Kobayashi","year":"2021","journal-title":"J ImmunoTher Cancer."},{"issue":"230","key":"2022092808412400200_CIT0034","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med."},{"key":"2022092808412400200_CIT0035","article-title":"Clinical heterogeneity of hypophysitis secondary to PD-1\/PD-L1 blockade: insights from four cases","volume":"2019","author":"Lupi","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"2","key":"2022092808412400200_CIT0036","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1210\/js.2018-00366","article-title":"Immune checkpoint blockade anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome","volume":"3","author":"Lanzolla","year":"2019","journal-title":"J Endocr Soc."},{"issue":"8","key":"2022092808412400200_CIT0037","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4158\/EP-2018-0472","article-title":"Baseline TSH level is associated with risk of anti-Pd-1-induced thyroid dysfunction","volume":"25","author":"Pollack","year":"2019","journal-title":"Endocr Pract."},{"issue":"9","key":"2022092808412400200_CIT0038","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nrendo.2014.114","article-title":"VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs","volume":"10","author":"Cao","year":"2014","journal-title":"Nat Rev Endocrinol."},{"issue":"11","key":"2022092808412400200_CIT0039","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1089\/thy.2015.0170","article-title":"Thyroid dysfunction in patients with metastatic carcinoma treated with sunitinib: is thyroid autoimmunity involved?","volume":"25","author":"Pani","year":"2015","journal-title":"Thyroid"},{"key":"2022092808412400200_CIT0040","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","article-title":"Targeting VEGF\/VEGFR to modulate antitumor immunity","volume":"9","author":"Yang","year":"2018","journal-title":"Front Immunol."},{"issue":"2","key":"2022092808412400200_CIT0041","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/thy.2010.0234","article-title":"Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma","volume":"21","author":"van Doorn","year":"2011","journal-title":"Thyroid"},{"issue":"9","key":"2022092808412400200_CIT0042","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1089\/thy.2010.0070","article-title":"Sorafenib-induced destructive thyroiditis","volume":"20","author":"Iavarone","year":"2010","journal-title":"Thyroid"},{"issue":"9","key":"2022092808412400200_CIT0043","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1507\/endocrj.EJ19-0140","article-title":"Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma","volume":"66","author":"Koizumi","year":"2019","journal-title":"Endocr J."},{"issue":"2","key":"2022092808412400200_CIT0044","doi-asserted-by":"crossref","first-page":"e000779","DOI":"10.1136\/jitc-2020-000779","article-title":"Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study","volume":"8","author":"Kobayashi","year":"2020","journal-title":"J ImmunoTher Cancer."},{"issue":"2","key":"2022092808412400200_CIT0045","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1507\/endocrj.EJ20-0371","article-title":"Distinct clinical features and prognosis between persistent and temporary thyroid dysfunctions by immune-checkpoint inhibitors","volume":"68","author":"Inaba","year":"2021","journal-title":"Endocr J."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac467\/45555459\/dgac467.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/10\/e4115\/46112675\/dgac467.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/10\/e4115\/46112675\/dgac467.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T08:46:35Z","timestamp":1664354795000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/10\/e4115\/6653516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":45,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,8,3]]},"published-print":{"date-parts":[[2022,9,28]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac467","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,8,3]]}}}